Dogwood Therapeutics (DWTX) News Today

Dogwood Therapeutics, Inc. (NASDAQ: DWTX) is likely trading higher on the back of a wave of upbeat analyst revisions from HC Wainwright. The firm maintained its Buy rating and $12.00 price target while materially raising earnings forecasts across multiple periods, suggesting improved expectations for the company’s profitability outlook.

• Positive Sentiment: HC Wainwright sharply raised its Q4 2026 EPS estimate for Dogwood Therapeutics to $0.14 from -$0.37, signaling a much better outlook for late-2026 profitability.
• Positive Sentiment: The analyst also boosted Q3 2026 EPS estimates to -$0.14 from -$0.34, Q2 2026 to -$0.13 from -$0.32, and FY2026 to -$0.56 from -$1.33.
• Positive Sentiment: FY2027 EPS estimates were lifted to -$0.60 from -$1.62, indicating expectations for a faster path toward earnings improvement. Source
• Neutral Sentiment: HC Wainwright also updated 2027 quarterly estimates to around -$0.15 EPS for Q1 through Q4, reflecting a steady, if still loss-making, long-term forecast. Source
• Neutral Sentiment: Separately, unrelated market roundup links mentioned Dogwood Therapeutics in a broader healthcare analyst-bullish theme, but there was no company-specific catalyst beyond the HC Wainwright note. Source

Overall, DWTX appears to be benefiting from improved analyst sentiment and higher earnings expectations, which can support the stock even though the company is still forecast to post losses in the near term.